Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicolaos Athienites

Nephrology Brockton, MA Medical Doctor

NPI 1902804107 CMS profile 176702

830 Oak St, 125E, Brockton, MA 02301

Open in the dashboard

General payments

$294,032

932 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicolaos Athienites of Brockton, MA is reported in the CMS Open Payments database as having received $294,032 across 932 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,154 85
2024 General $6,447 123
2023 General $28,686 158
2022 General $32,652 145
2021 General $68,525 158
2020 General $18,389 68
2019 General $135,178 195

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicolaos Athienites
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Nicolaos Athienites were reported at $4,154. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Nicolaos Athienites Nephrology median Middle half National median
2019 $135,178 $236 $90–$588 $163
2020 $18,389 $135 $46–$364 $114
2021 $68,525 $202 $67–$551 $132
2022 $32,652 $242 $77–$695 $149
2023 $28,686 $254 $84–$766 $160
2024 $6,447 $300 $99–$852 $164
2025 $4,154 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Horizon Therapeutics plc $105,503 171 payments
  2. AstraZeneca Pharmaceuticals LP $95,101 147 payments
  3. Mallinckrodt Enterprises LLC $38,193 29 payments
  4. ANI Pharmaceuticals, Inc. $19,935 125 payments
  5. Retrophin, Inc. $15,042 63 payments
  6. Mallinckrodt Hospital Products Inc. $11,293 35 payments
  7. Relypsa, Inc. $1,762 73 payments
  8. Fresenius USA Marketing, Inc. $1,254 15 payments
  9. Otsuka America Pharmaceutical, Inc. $886 43 payments
  10. OPKO Pharmaceuticals, LLC $785 42 payments
  11. Other $4,278 189 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $114,600 58 payments
  2. Honoraria $108,449 71 payments
  3. Travel and Lodging $43,710 94 payments
  4. Food and Beverage $18,527 646 payments
  5. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $6,150 4 payments
  6. Consulting Fee $1,761 2 payments
  7. Education $835 57 payments
Products named General payments · program years 2019–2025
  1. KRYSTEXXA $105,503 171 payments
  2. LOKELMA $92,724 136 payments
  3. ACTHAR Autoimmune And Rare Disease $38,193 29 payments
  4. PURIFIED CORTROPHIN GEL Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA $12,792 76 payments
  5. ACTHAR Immunology $11,293 35 payments
  6. (815) Thiola $7,326 12 payments
  7. PURIFIED CORTROPHIN GEL Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA $7,142 49 payments
  8. FARXIGA $2,377 11 payments
  9. Velphoro $1,237 14 payments
  10. Veltassa $950 39 payments
  11. Other $6,845 324 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

990

Median for Nephrology: 954

Drug cost

$66,941

Median for Nephrology: $127,050

Branded share of claims

5.6%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lokelma Sodium Zirconium Cyclosilicate Brand 18 $22,086
Rayaldee Calcifediol Brand 12 $13,311
Farxiga Dapagliflozin Propanediol Brand 13 $7,608
Sevelamer Carbonate Generic 33 $7,378
Calcium Acetate Generic 56 $3,051
Calcitriol Generic 105 $2,011
Olmesartan Medoxomil Generic 16 $1,970
Torsemide Generic 48 $894
Labetalol Hcl Generic 16 $865
Amlodipine Besylate Generic 89 $736

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$308,093

Medicare's payments for the services billed

Medicare patients

666

Average age 76

Services billed

2,334

319 women, 347 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 53%
Arthritis 53%
Heart failure 50%
Ischemic heart disease 50%
Atrial fibrillation 37%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
$4,447 — —
INJECTAFER
$279 — —
FARXIGA
$225 13 —
Kerendia
$164 — —
TAVNEOS
$162 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

932 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record